XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.2
License Agreements - Novartis (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended 176 Months Ended
Nov. 30, 2009
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Dec. 31, 2023
License Agreements              
Total revenues   $ 1,043,759 $ 954,610 $ 1,924,648 $ 1,763,283    
JAKAFI              
License Agreements              
Total revenues   705,973 682,384 1,277,812 1,262,353    
Novartis | JAKAFI | UNITED STATES              
License Agreements              
Total revenues   34,600 33,500 57,600 56,900    
Royalties payable   433,200   433,200   $ 433,200 $ 375,600
Novartis | JAKAVI              
License Agreements              
Total revenues   99,300 90,400 188,900 167,100    
Novartis | TABRECTA              
License Agreements              
Total revenues   $ 5,300 $ 4,800 $ 10,500 $ 9,000    
Maximum | Novartis | JAKAVI              
License Agreements              
Royalty payments on future global net sales (as a percent)       14.00%      
Minimum | Novartis | JAKAVI              
License Agreements              
Royalty payments on future global net sales (as a percent)       12.00%      
Development Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           157,000  
Development Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement $ 174,000            
Regulatory Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           345,000  
Regulatory Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement 495,000            
Commercialization Milestones | Novartis              
License Agreements              
Amount recognized and received for the achievement of a predefined milestone           $ 200,000  
Commercialization Milestones | Maximum | Novartis              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement 500,000            
Development and Regulatory Milestones | Maximum | Novartis | GVHD              
License Agreements              
Upfront and immediate milestone payment to be received under license agreement $ 75,000